

Part VI: Summary of the risk management plan

Summary of risk management plan for Dabigatran etexilate STADA (Dabigatran)

This is a summary of the risk management plan (RMP) for Dabigatran etexilate Stada. The RMP details important risks of Dabigatran etexilate Stada, how these risks can be minimised, and how more information will be obtained about Dabigatran etexilate Stada's risks and uncertainties (missing information).

Dabigatran etexilate Stada's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Dabigatran etexilate Stada should be used.

Important new concerns or changes to the current ones will be included in updates of Dabigatran etexilate Stada's RMP.

I. The medicine and what it is used for

Dabigatran etexilate Stada is authorised for the primary prevention of VTE in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery; the treatment of VTE and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age; the prevention of stroke and systemic embolism in adult patients with NVAf, with one or more risk factors; and the treatment of DVT and PE, and prevention of recurrent DVT and PE in adults (see SmPC for the full indication). It contains dabigatran as the active substance and it is given orally.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Dabigatran etexilate Stada, together with measures to minimise such risks and the proposed studies for learning more about Dabigatran etexilate Stada's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In the case of Dabigatran etexilate Stada, these measures are supplemented with *additional risk minimisation measures* mentioned under relevant important risks, below.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Dabigatran etexilate Stada is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Dabigatran etexilate Stada are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Dabigatran etexilate Stada. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	<ul style="list-style-type: none"> • Haemorrhage
Important potential risks	<ul style="list-style-type: none"> • None
Missing information	<ul style="list-style-type: none"> • Patients aged 0 to 2 years who were born prematurely¹ • Paediatric patients with renal dysfunction (eGFR <50ml/min)¹

¹ these safety concerns are only valid in countries where the paediatric indication is approved.

II.B Summary of important risks

Haemorrhage	
Important identified risk	
Risk minimisation measures	Routine risk minimisation measures: Listed in SmPC sections 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 Additional risk minimisation measures: Educational materials (physician educational packs for each therapeutic indication containing SmPC, prescriber guide, patient alert card)
Additional pharmacovigilance activities	Additional pharmacovigilance activities: None

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Dabigatran etexilate Stada.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Dabigatran etexilate Stada.